NASDAQ:AKTX Akari Therapeutics Q4 2025 Earnings Report $10.94 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$10.50 -0.45 (-4.07%) As of 06/18/2026 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Akari Therapeutics EPS ResultsActual EPS-$2.68Consensus EPS -$0.03Beat/MissMissed by -$2.65One Year Ago EPSN/AAkari Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAkari Therapeutics Announcement DetailsQuarterQ4 2025Date3/30/2026TimeAfter Market ClosesConference Call DateMonday, March 30, 2026Conference Call Time7:00AM ETUpcoming EarningsAkari Therapeutics' Q2 2026 earnings is estimated for Tuesday, August 18, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, August 19, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) Akari Therapeutics Earnings HeadlinesAkari Therapeutics (NASDAQ:AKTX) Shares Cross Above 50-Day Moving Average - Time to Sell?June 16 at 3:19 AM | americanbankingnews.comAkari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari’s Differentiated PH1 Payload Platform Following ASCO 2026June 6, 2026 | markets.businessinsider.comRead this warning immediatelyPorter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.June 19 at 1:00 AM | Porter & Company (Ad)Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari's Differentiated PH1 Payload Platform Following ASCO 2026June 4, 2026 | globenewswire.comAkari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor “What This Means” Segment Following ASCO Abstract AcceptanceMay 28, 2026 | globenewswire.comAkari Therapeutics PLC ADR AKTXMay 26, 2026 | morningstar.comMSee More Akari Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Akari Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Akari Therapeutics and other key companies, straight to your email. Email Address About Akari TherapeuticsAkari Therapeutics (NASDAQ:AKTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders. Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease. In addition, the company is advancing coversin, a small‐protein C5 inhibitor with potential applications in ophthalmology and hematology. These programs leverage Akari’s proprietary platform chemistry to achieve high specificity and subcutaneous dosing convenience. Headquartered in London, United Kingdom, with research and development operations in the United States, Akari Therapeutics was founded to translate cutting-edge complement science into first-in-class medicines. The company is led by an experienced management team with deep expertise in immunology, drug development and regulatory affairs, and it collaborates with academic institutions and patient organizations to support global clinical studies and future commercialization efforts. View Akari Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Satellogic Is Tiny But Its Revenue Growth Is Hard to IgnoreAehr Spikes on New Order, But Has Stock Gotten Ahead of Itself?Why Kroger’s Pullback Could Be a Gift for Patient InvestorsCredo Technologies Accelerates AI—Its Stock Price Will FollowWhy Palantir’s Google Cloud Deal Could Change the DebateAmerican Eagle’s Q1 Beat Leaves Investors With a Bigger QuestionCarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge Upcoming Earnings FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
